Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H18ClN5O2S2 |
Molecular Weight | 520.026 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(SCC2=CSC(=N2)C3=CC=C(Cl)C=C3)=C(C#N)C(C4=CC=C(OCCO)C=C4)=C1C#N
InChI
InChIKey=CITWCLNVRIKQAF-UHFFFAOYSA-N
InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)
Molecular Formula | C25H18ClN5O2S2 |
Molecular Weight | 520.026 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Capadenoson (BAY 68-4986) is a nonnucleoside agonist for the A1 Adenosine Receptor (A1AR) and the A2BAR. Capadenoson has undergone two Phase IIa clinical trials, initially in patients with atrial fibrillation and subsequently in patients with stable angina. Capadenoson has also been shown to decrease cardiac remodeling in an animal model of advanced heart failure and a capadenoson derivative, neladenoson bialanate, recently entered clinical development for the treatment of chronic heart failure. The therapeutic effects of capadenoson are currently thought to be mediated through the A1AR.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21185259 | https://www.ncbi.nlm.nih.gov/pubmed/21464936
Curator's Comment: # Bayer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21185259 |
0.1 nM [EC50] | ||
Target ID: CHEMBL255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28344125 |
8.94 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg single, oral Highest studied dose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: Page: p.589 |
unhealthy, ADULT n = 10 Health Status: unhealthy Condition: coronary artery disease Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 10 Sources: Page: p.589 |
PubMed
Title | Date | PubMed |
---|---|---|
A1 adenosine receptor agonists and their potential therapeutic applications. | 2008 Dec |
|
Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism. | 2011 Mar 28 |
|
Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. | 2013 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22370739
In a randomized, double-blind, placebo-controlled, single dose-escalating, multicenter trial the effect of capadenoson at 1, 2.5, 5, 10, and 20 mg was compared versus placebo. Sixty-two male patients with stable angina were enrolled in the study. There was a consistent trend for heart rate reduction at comparable maximum work load in active treatment groups, with significant differences against placebo for 10 and 20 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21464936
In isolated perfused hearts of Wistar and Spontaneously Hypertensive Rats (SHR), norepinephrine release was induced by electrical stimulation under control conditions (S1), and with capadenoson 60 nM (30 µg/l)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:15:42 GMT 2023
by
admin
on
Fri Dec 15 17:15:42 GMT 2023
|
Record UNII |
O519NVW73R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000127411
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
C87279
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
9936489
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
8723
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL3235279
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
O519NVW73R
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
SUB33447
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
544417-40-5
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY | |||
|
DTXSID50969597
Created by
admin on Fri Dec 15 17:15:42 GMT 2023 , Edited by admin on Fri Dec 15 17:15:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|